Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Kala Bio’s CHASE trial misses primary endpoint, KPI-012 development discontinued | Ophthalmology Times
(Image Credit: AdobeStock) Kala Bio announced that CHASE (NCT05727878), its phase 2b clinical trial of KPI-012 for persistent corneal epithelial defect (PCED), did not meet its primary endpoint. Additionally, the company noted that the trial failed to show statistical significance…
Q&A: Mark Gillies the outcomes of injecting VEGF inhibitors | Ophthalmology Times
Photo of Mark Gillies at the 2025 EURETINA meeting Mark Gillies, MD, PhD, introduced the Fight Retinal Blindness! Project, a comprehensive registry tracking VEGF inhibitor eye injection outcomes since 2007. Spanning 20 countries with 150 active practitioners, the project uniquely…
The Netherlands: Lupin strengthens ophthalmology business with acquisition of VISUfarma from GHO Capital
\n European specialist investor GHO Capital Partners has announced the sale of its portfolio company, VISUfarma, a Netherlands-headquartered specialty pharmaceutical company focused on ophthalmology, to global pharma major Lupin. \n\n\n\n VISUfarma was created by GHO Capital in 2016 by combining…
Q&A: Harvey Uy on the power of digital images and records | Ophthalmology Times
Photo of Harvey Uy, MD, DPBO, FVRSP, at the 2025 EURETINA meeting Harvey Uy, MD, DPBO, FVRDP, a retina specialist from the Peregrine Eye and Laser Institute in the Philippines, discussed the transformative power of digital image management in ophthalmology.…
Q&A: Prem S. Subramanian, MD, PhD, on neuro-ophthalmic insights at EyeCon 2025 | Ophthalmology Times
Prem S. Subramanian, MD, PhD, emphasized the importance of pattern recognition in distinguishing ocular from neurologic causes of visual symptoms during EyeCon 2025. (Image credit: AdobeStock/ryandi) “Pattern recognition is key,” emphasized Prem S. Subramanian, MD, PhD, as he discussed the…
Q&A: Marion Munk discusses the phase 2a BETTER study | Ophthalmology Times
Photo of Marion Munk at EURETINA 2025 In her conversation with the Eye Care Network, Marion Munk, MD, PhD, details a promising phase 2a clinical study of ISTH0036, an oligonucleotide antisense drug targeting TGF-β2. Developed to address fibrosis in neovascular…
EyeCon 2025: Adopting an interventional glaucoma mindset with Oluwatosin U. Smith, MD | Ophthalmology Times
At this year’s EyeCon meeting, Oluwatosin U. Smith, MD, of the Glaucoma Associates of Texas, reflected on her dual role—both as an educator and a leader in its development—while delivering a focused presentation on the current state of glaucoma care.…
MacuMira launches first Health Canada-approved device for AMD treatment | Ophthalmology Times
(Image Credit: AdobeStock) Canadian medical device company MacuMira Medical Devices recently introduced the first Health Canada-approved treatment to improve visual function for patients with dry age-related macular degeneration (AMD).1 This new technology, the MacuMira system, is a non-invasive treatment now…
EyeCon 2025 celebrates Visionary in Eye Care Resident Award winners | Ophthalmology Times
The recipients of this year’s Visionary in Eye Care Resident Recognition Awards were revealed at the Ophthalmology Times and Optometry Times EyeCon® 2025 conference, held September 26 and 27 at the Margaritaville Hollywood Beach Resort, in Hollywood, Florida. The program…
STAAR and Broadwood clash over proposed Alcon merger | Ophthalmology Times
(Image Credit: AdobeStock) STAAR and Broadwood Partners have recently pleaded their case in the proposed merger between STAAR and Alcon, issuing statements both for and against the move, respectively. This follows the expiration of the “window shop” period in the…